In this issue:
- DAA therapy and complications of CHC
- Statin use and HCC risk in patients with NAFLD
- Peginterferon lambda for CHD
- Perinatal immunoprophylaxis for infants born to women with HBV
- Severe acute hepatitis of unknown origin in children
- DAAs for HCV in advanced CKD
- Significant histological disease in chronic grey zone HBV
- Global treatment rate and barriers to DAA therapy
- Australian trends in retreatment of HCV
- Detection and treatment of HCV at addiction centres
Please login below to download this issue (PDF)